2026 GLP–1 Consumer Survey
2026 Healthline GLP–1 Consumer Survey – Sample size: 1,007 total = 720 currently taking a GLP–1, 203 took a GLP–1 in the past, 84 currently considering a GLP–1. 53% female and 47% male.
Among people taking a GLP–1 for both
weight loss and diabetes:
expected 6
to 12 months
Among people taking a GLP–1 for weight
loss, treatment length expectations were
as follows:
Among people taking a GLP–1 specifically
for diabetes or blood sugar management:
expected indefinite or lifelong treatment
expected 3
to 4 years
expected to remain on it for less than 6 months
expected 1
to 2 years
27%
8%
8%
6%
33%
expected 1
to 2 years
expected 6
to 12 months
expected 3
to 4 years
expected at least 5 years
expected treatment to last less than 6 months
27%
12%
6%
4%
3%
expected
indefinite or
lifelong treatment
21%
expected 2 years
or less
were unsure
expected indefinite treatment
41%
22%
22%
